SBRT compared to sorafenib in locally advanced hepatocellular carcinoma: a propensity score analysis

被引：0

作者：

Gkika, E. ^{[1
]}

Brunner, T. ^{[2
]}

Abbasi-Senger, N. ^{[3
]}

Alheit, H.

Baus, W. ^{[4
]}

Blanck, O. ^{[5
]}

Gerum, S. ^{[6
]}

Guckenberger, M. ^{[7
]}

Habermehl, D. ^{[8
]}

Ostheimer, C. ^{[9
]}

Riesterer, O. ^{[7
]}

Tamihardja, J. ^{[10
]}

Pinato, D. J. ^{[11
]}

Rimassa, L. ^{[12
]}

Pressiani, T. ^{[12
]}

Schultheiss, M. ^{[13
]}

Sharma, R. ^{[11
]}

Burlone, M. E. ^{[14
]}

Pirisi, M. ^{[14
]}

Kudo, M. ^{[15
]}

Park, J. W. ^{[16
]}

Neumann-Haefelin, C. ^{[17
]}

Grosu, A. ^{[18
]}

Thimme, R. ^{[17
]}

Bettinger, D. ^{[17
]}

机构：

[1] Uniklin Freiburg, Radiat Oncol, Freiburg, Germany

[2] Univ Magdeburg, Radiat Oncol, Magdeburg, Germany

[3] Univ Jena, Radiat Oncol, Jena, Germany

[4] Univ Hosp Cologne, Radiat Oncol, Cologne, Germany

[5] Univ Med Ctr Schleswig Holstein, Dept Radiat Oncol, Campus Kiel, Kiel, Germany

[6] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Munich, Germany

[7] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland

[8] Tech Univ Munich, Dept Radiat Oncol, Klinikum Rechts Isar, Munich, Germany

[9] Martin Luther Univ Halle Wittenberg, Dept Radiat Oncol, Halle, Germany

[10] Univ Hosp Wurzburg, Dept Radiat Oncol, Wurzburg, Germany

[11] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp, London, England

[12] Humanitas Canc Ctr, Humanitas Clin & Res Ctr, Med Oncol & Hematol Unit, Milan, Italy

[13] Univ Freiburg, Med Ctr, Dept Med 2, Freiburg, Germany

[14] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[15] Kindai Univ, Sch Med, Dept Gastroenterol & Hepatol, Osakasayama, Japan

[16] Natl Canc Ctr Hosp, Ctr Liver Canc, Goyang, South Korea

[17] Univ Freiburg, Med Ctr, Dept Med 2, Freiburg, Germany

[18] Univ Freiburg, Dept Radiat Oncol, Med Ctr, Freiburg, Germany

来源：

RADIOTHERAPY AND ONCOLOGY | 2019年 / 133卷

关键词：

D O I：

10.1016/S0167-8140(19)31231-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO-0811

引用

页码：S423 / S423

页数：1

共 50 条

[1] Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis
Kim, Gun Ha
Choi, Sang Lim
Kim, Jin Hyoung
Shim, Ju Hyun
Alali, Meshari
Kim, Nayoung
LIFE-BASEL, 2021, 11 (10):
[2] Sorafenib/SBRT Yields OS Benefit in Locally Advanced Hepatocellular Carcinoma
Seymour, Caroline
ONCOLOGY-NEW YORK, 2023, 37 (03): : 148 - 148
[3] Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis
Martelletti, Carolina
Ricotti, Andrea
Gesualdo, Marcantonio
Carucci, Patrizia
Gaia, Silvia
Rolle, Emanuela
Burlone, Michela Emma
Okolicsanyi, Stefano
Mattalia, Alberto
Pirisi, Mario
Berchialla, Paola
Tabone, Marco
JOURNAL OF DIGESTIVE DISEASES, 2021, 22 (08) : 496 - 502
[4] Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis
Gramenzi, Annagiulia
Golfieri, Rita
Mosconi, Cristina
Cappelli, Alberta
Granito, Alessandro
Cucchetti, Alessandro
Marinelli, Sara
Pettinato, Cinzia
Erroi, Virginia
Fiumana, Silvia
Bolondi, Luigi
Bernardi, Mauro
Trevisani, Franco
LIVER INTERNATIONAL, 2015, 35 (03) : 1036 - 1047
[5] Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
Qin, Jian
Huang, Yusheng
Zhou, Hanjing
Yi, Shouhui
FRONTIERS IN ONCOLOGY, 2022, 12
[6] Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis
Bettinger, Dominik
Pinato, David J.
Schultheiss, Michael
Sharma, Rohini
Rimassa, Lorenza
Pressiani, Tiziana
Burlone, Michela E.
Pirisi, Mario
Kudo, Masatoshi
Park, Joong Won
Buettner, Nico
Neumann-Haefelin, Christoph
Boettler, Tobias
Abbasi-Senger, Nasrin
Alheit, Horst
Baus, Wolfgang
Blanck, Oliver
Gerum, Sabine
Guckenberger, Mathias
Habermehl, Daniel
Ostheimer, Christian
Riesterer, Oliver
Tamihardja, Joerg
Grosu, Anca-Ligia
Thimme, Robert
Brunner, Thomas Baptist
Gkika, Eleni
LIVER CANCER, 2019, 8 (04) : 281 - 294
[7] Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis
Liu, Chieh-Min
Huang, Bing-Shen
Yen, Yi-Hao
Wang, Yu-Ming
Huang, Eng-Yen
Hsu, Hsuan-Chih
Huang, Tzu-Ting
Yang, Yao-Hsu
Cheng, Jen-Yu
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 963 - 973
[8] COST EFFECTIVENESS OF SORAFENIB VERSUS SBRT FOR ADVANCED HEPATOCELLULAR CARCINOMA
Chan, A.
Leung, H.
VALUE IN HEALTH, 2016, 19 (03) : A152 - A152
[9] Phase I Study of Sorafenib and SBRT for Advanced Hepatocellular Carcinoma
Dawson, L. A.
Brade, A.
Cho, C.
Kim, J.
Brierley, J.
Dinniwell, R.
Wong, R.
Ringash, J.
Cummings, B.
Knox, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S10 - S11
[10] Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Kuo, Yuan-Hung
Lu, Sheng-Nan
Chen, Yen-Yang
Kee, Kwong-Ming
Yen, Yi-Hao
Hung, Chao-Hung
Hu, Tsung-Hui
Chen, Chien-Hung
Wang, Jing-Houng
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →